In one study, melanoma patients with the highest fold expansions of these ICOS+ Treg-like cells following TIL therapy and HD-IL-2 were noted to have worse clinical outcomes than patients with fewer ICOS+ Tregs (231). This evidence concerns the gene ICOS and melanoma.